Stock Price

DICK'S and adidas aren't just selling jerseys for the World Cup. They're executing a multi-billion dollar playbook to conquer North America's soccer boom.

The tech-first insurer enters the Peace Garden State, betting its AI-powered app, low prices, and B-Corp mission can reshape a traditional market.

Fresh Del Monte becomes Del Monte Corporation in a bold move to unite its fragmented global brand. We analyze the strategy, the risks, and the future.

With a Halliburton deal and $70M in hand, Greenland Energy is chasing a 13-billion-barrel prize. It's a high-risk play pitting economic hope against Arctic fragility.

UEC ignites production at America's largest new uranium mine, a major step toward US energy independence. While navigating temporary cost hikes, its robust finances and bold unhedged strategy position it to capitalize on a tightening global market.

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

XAUE launches a yield-bearing, gold-backed gift card, moving digital assets from niche investment to mainstream corporate rewards. But can it deliver?

A new global tax regime is here, and the UK's first deadline looms. For CFOs, it's a data nightmare. Can new software provide the critical lifeline?

A major U.S. fund's increased stake in KT&G signals deep trust in its global expansion, backed by record Q1 growth and a promise of richer dividends.

With a strategic offering led by Roth Canada and BMO, 1911 Gold aims to fund the final push for its historic True North Project's 2027 revival.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

BMTC Group posts a dramatically improved bottom line, but a closer look reveals a struggling retail core being propped up by market gains and a risky bet on real estate.

With a complex $72M financing deal, Park Systems is doubling down on its dominance in nanometrology. Is this the move that makes them indispensable to chip giants?

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

A major stock conversion aims to save Alpha Modus from Nasdaq delisting. Is it a savvy financial maneuver or a last-ditch effort for its AI ambitions?

As National Outlet Shopping Day returns, it's more than a sale. It's Simon's blueprint for the future of retail and a key test of consumer spending.

Beta Bionics faces a shareholder investigation after a slowdown in patient growth spooked investors. We decode the numbers and the broader risks of growth metrics.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

A routine board appointment at Bitcoin firm Twenty One Capital masks a major power shift. As Tether buys out SoftBank, is this a move toward legitimacy or a quiet coup?

EQT appoints M&A mastermind Gustav Segerberg as CFO, signaling a doubling-down on its aggressive growth strategy. What does this mean for its future?